Blue Cell Therapeutics ApS

Egen beskrivelse på virk.dk

Description of key activities of the companyThe principal activity of the Company is the development of novel adipose-derived mesenchymal stem cell (MSC) therapies for the treatment of chronic diseases, with erectile dysfunction (ED) as the lead indication. There is a large unmet clinical need for regenerative treatment of chronic diseases. Stem cell populations, including adipose-derived regenerative cells (ADRCs), are heterogeneous, and the understanding of their in vivo origin and properties remains incomplete. Stem cell therapies hold the potential to modify the underlying course of disease rather than its symptoms; realising this potential requires robust clinical and quality data to meet regulatory requirements for approval. In prior academic Phase I work, a single injection of autologous ADRCs was associated with reversal of erectile dysfunction in treated men, establishing the clinical rationale for the Company's approach. Building on this, the Company has developed a proprietary allogeneic cell-culturing method that enables production of up to 100,000 patient doses from a single donor, supporting a scalable, off-the-shelf product with a low cost of goods. A patent application covering this method has been filed. The Company's near-term objectives are to manufacture its lead allogeneic cell product, BlueC-231, under Good Manufacturing Practice (GMP) conditions, to transition the process from 2D to 3D culture, to generate the required quality-control and characterisation data, to complete the necessary nonclinical toxicology studies, and to obtain regulatory authorisation to advance into a regulatory clinical trial of the cultured lead product. In addition, we have obtained data regarding the product, BlueC-231s positive effect in Pulmonary Arterial Hypertension, a disease which shares pathophysiological molecular pathways with ED. The Company's mission is to translate knowledge from basic science and preclinical models into approved treatments for chronic diseases — beginning with erectile dysfunction — using cultured allogeneic stem cells with angiogenic and regenerative properties. The Company's goal is to establish Blue Cell's ED therapy as a standard of care in hospitals and clinics and to make it available to patients internationally.